by The formulation development outsourcing market size is poised to grow by USD 75.8 billion by 2032 from USD 37.4 billion in 2022, exhibiting a CAGR of 7.32% during the forecast period 2023-2032.
Key Takeaways:
- By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
- By service, the formulation development generated over 77% of revenue share in 2022.
- By formulation, the oral segment had the largest market share of 64% in 2022.
- By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
- By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Formulation development outsourcing market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Formulation development outsourcing Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3192
Formulation Development Outsourcing Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 40.14 Billion |
| Market Size by 2032 | USD 75.8 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.32% |
| Largest Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Service, By Formulation, By Therapeutic Area, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Carbonated Beverage Market Size To Rake USD 654.37 Bn By 2032
The empirical study on the global Formulation development outsourcing market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Formulation development outsourcing Market. Our market report for the Formulation development outsourcing market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- SGS S.A.
- Eurofins Scientific SE
- Element
- Labcorp
- Thermo Fisher Scientific, Inc. (Patheon)
- Intertek Group plc
- Recipharm
- Lonza
- Charles River Laboratories International, Inc.
- Catalent Inc.
Data Sources and Methodology
To gather comprehensive insights on the Global Formulation development outsourcing Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Formulation development outsourcing Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Formulation development outsourcing market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Formulation Development Outsourcing Market Segmentation:
By Service
- Preformulation
- Formulation Development
By Formulation
- Topical
- Oral
- Injectable
- Others
By Therapeutic Area
- Oncology
- Infectious Disease
- Respiratory
- Cardiovascular
- Neurology
- Hematology
- Dermatology
- Others
By End-User
- Pharmaceutical Industries
- Research and Academic Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Formulation development outsourcing market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Formulation development outsourcing market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Formulation development outsourcing market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Formulation development outsourcing market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market
5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Formulation Development Outsourcing Market, By Service
8.1. Formulation Development Outsourcing Market, by Service, 2023-2032
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Formulation Development Outsourcing Market, By Formulation
9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area
10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Infectious Disease
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Respiratory
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cardiovascular
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Neurology
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Hematology
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Dermatology
10.1.7.1. Market Revenue and Forecast (2020-2032)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Formulation Development Outsourcing Market, By End-User
11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032
11.1.1. Pharmaceutical Industries
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Research and Academic Institutions
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 13. Company Profiles
13.1. SGS S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Element
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Labcorp
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific, Inc. (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Recipharm
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lonza
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories International, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Catalent Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
About Us:
Our team comprises a dedicated group of research analysts and management consultants who are driven by a unified vision: assisting individuals and organizations in realizing their strategic objectives, both immediate and long-term, through the provision of comprehensive research services. At Precedence Research, we have positioned ourselves to cater to the needs of a diverse range of entities, including established companies, startups, and non-profit organizations across various sectors. Our expertise extends to industries such as packaging, automotive, healthcare, chemicals and materials, industrial automation, consumer products, electronics and semiconductors, IT and telecommunications, and energy. With a wealth of experience within our ranks, our skilled analysts are equipped with extensive knowledge of the research landscape.
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
